Trust Co. of Vermont trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 12.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,166 shares of the company’s stock after selling 1,270 shares during the period. Trust Co. of Vermont’s holdings in Eli Lilly and were worth $754,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Heritage Trust Co acquired a new stake in Eli Lilly and during the 1st quarter valued at $135,000. Point72 Asia Hong Kong Ltd increased its holdings in Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after purchasing an additional 1,239 shares in the last quarter. Penserra Capital Management LLC increased its holdings in Eli Lilly and by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after purchasing an additional 176 shares in the last quarter. American National Bank increased its holdings in Eli Lilly and by 5.2% during the 2nd quarter. American National Bank now owns 2,088 shares of the company’s stock valued at $172,000 after purchasing an additional 104 shares in the last quarter. Finally, Sandy Spring Bank increased its holdings in Eli Lilly and by 51.8% during the 1st quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock valued at $185,000 after purchasing an additional 750 shares in the last quarter. 75.72% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Eli Lilly and Company (LLY) Position Trimmed by Trust Co. of Vermont” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/09/23/eli-lilly-and-company-lly-position-trimmed-by-trust-co-of-vermont.html.

A number of research firms recently weighed in on LLY. BidaskClub raised Eli Lilly and from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. Barclays PLC raised their price target on Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Tuesday, July 4th. BMO Capital Markets reaffirmed a “sell” rating and set a $73.00 price target on shares of Eli Lilly and in a report on Friday, August 4th. Berenberg Bank reaffirmed a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a report on Thursday, July 27th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $96.00 price target (up from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. Eli Lilly and currently has an average rating of “Hold” and an average price target of $88.27.

Eli Lilly and Company (LLY) traded up 0.70% on Friday, hitting $83.91. The stock had a trading volume of 3,148,723 shares. The company has a market capitalization of $88.53 billion, a PE ratio of 36.31 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72. The company has a 50 day moving average of $80.84 and a 200 day moving average of $82.02.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.86 earnings per share. On average, equities analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current year.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 590,000 shares of company stock valued at $48,551,300 over the last 90 days. 0.20% of the stock is currently owned by company insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.